Skip to content
vernakalant

Structure via PubChem · Public domain (PubChem)

EntityQ665725· pop 11· linked from 349 articles

vernakalant

Sign in to save

Also known as RSD1235, (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol

Vernakalant, sold under the brand name Brinavess, is a class III antiarrhythmic drug for the acute conversion of atrial fibrillation, in form of an intravenous infusion. It has been approved for use in the European Union and the United Kingdom since 2010. The US Food and Drug Administration denied approval in 2008 and 2019.

Chemical data

Formula
C20H31NO4
Molecular weight
349.5 g/mol
IUPAC name
(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
SMILES
COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC
InChIKey
VBHQKCBVWWUUKN-KZNAEPCWSA-N
XLogP
2.9
Polar surface area
51.2 Ų
H-bond donors
1
H-bond acceptors
5
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Small molecule
First approval
2010
Indications
atrial fibrillation, atrial flutter, cardiac arrhythmia

via ChEMBL · EBI

Wikidata facts

Mass
349.225
Show 3 more facts
chemical formula
C₂₀H₃₁NO₄
isomeric SMILES
COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC
canonical SMILES
COC1=C(C=C(C=C1)CCOC2CCCCC2N3CCC(C3)O)OC
Sources (2)

via Wikidata · CC0

~7 min read

Encyclopedic overview

11 sections
Contents
  • Medical uses
  • Contraindications
  • Side effects
  • Overdose
  • Interactions
  • Pharmacology
  • Mechanism of action
  • Pharmacokinetics and pharmacogenomics
  • Chemistry
  • History
  • References

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 446573380 | IUPAC_name = (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidin-3-ol | image = Vernakalant.svg | image_class = skin-invert-image | alt =

| tradename = Brinavess | pregnancy_AU = | pregnancy_category = | routes_of_administration = Intravenous, | ATC_prefix = C01 | ATC_suffix = BG11

Excerpted from Wikipedia’s “vernakalant” article, available under the CC BY-SA 4.0 licence.